We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B Turnover 32.84%
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.1%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$393M
AUM Growth
+$6.69M
Cap. Flow
+$2.85M
Cap. Flow %
0.72%
Top 10 Hldgs %
57.16%
Holding
48
New
12
Increased
9
Reduced
16
Closed
1
Avg Time Held
1 year
Top 10 Avg Time Held
1.2 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
XENE icon
Xenon Pharmaceuticals
XENE
+$5.39M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.61M
3
HROW icon
Harrow
HROW
+$4.38M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$3.44M
5
CLLS icon
Cellectis
CLLS
+$3.16M

Top Sells

Rank Stock Value
1
KYNB icon
Kyntra Bio
KYNB
+$9.86M
2
AXGN icon
Axogen
AXGN
+$6.11M
3
VKTX icon
Viking Therapeutics
VKTX
+$4.46M
4
BFRA
Biofrontera AG American Depositary Shares
BFRA
+$4.24M
5
BPMC icon
Blueprint Medicines
BPMC
+$3.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
CDTX icon
26
DELISTED
Cidara Therapeutics
CDTX
$5.28M 1.34%
60,000
– –
2018 Q2
1 quarter
CORI
27
DELISTED
Corium International, Inc.
CORI
$5.23M 1.33%
550,000
-250,000
-31% -$2.15M
2015 Q4
11 quarters
CMRX icon
28
DELISTED
Chimerix, Inc.
CMRX
$4.61M 1.17%
1,185,000
+35,000
+3% +$149K
2016 Q1
10 quarters
HROW icon
29
Harrow
HROW
$1.08B
$4.5M 1.15%
+1,620,000
New +$4.38M
2018 Q3
0 quarters
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$3.4B
$4.05M 1.03%
+195,000
New +$3.07M
2018 Q3
0 quarters
IOVA icon
31
Iovance Biotherapeutics
IOVA
$6.67B
$3.66M 0.93%
+325,000
New +$4.61M
2018 Q3
0 quarters
CTIC
32
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.35M 0.85%
1,550,000
+1,388,600
+860% +$3.44M
2018 Q2
1 quarter
TVRD icon
33
Tvardi Therapeutics
TVRD
$14.3M
$3.11M 0.79%
+3,611
New +$2.61M
2018 Q3
0 quarters
ARQL
34
DELISTED
Arqule Inc
ARQL
$3.11M 0.79%
550,000
+130,000
+31% +$740K
2018 Q2
1 quarter
CLLS icon
35
Cellectis
CLLS
$111M
$3.1M 0.79%
+110,000
New +$3.16M
2018 Q3
0 quarters
ARDX icon
36
Ardelyx
ARDX
$844M
$2.83M 0.72%
+650,000
New +$2.71M
2018 Q3
0 quarters
EPZM
37
DELISTED
Epizyme, Inc
EPZM
$2.12M 0.54%
200,000
-75,000
-27% -$856K
2018 Q1
2 quarters
TGTX icon
38
TG Therapeutics
TGTX
$8.57B
$1.96M 0.5%
350,000
-275,000
-44% -$3.14M
2018 Q1
2 quarters
PLX icon
39
Protalix BioTherapeutics
PLX
$210M
$1.82M 0.46%
250,000
-60,000
-19% -$301K
2017 Q4
3 quarters
CMTA
40
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$1.66M 0.42%
+148,832
New +$1.57M
2018 Q3
0 quarters
TCDA
41
DELISTED
Tricida, Inc. Common Stock
TCDA
$1.56M 0.4%
+51,000
New +$1.5M
2018 Q3
0 quarters
BFRA
42
DELISTED
Biofrontera AG American Depositary Shares
BFRA
$1.07M 0.27%
79,007
-312,393
-80% -$4.24M
2018 Q2
1 quarter
DERM icon
43
DELISTED
Dermira, Inc.
DERM
$1.06M 0.27%
+97,400
New +$982K
2018 Q3
0 quarters
ACHN
44
DELISTED
Achillion Pharmaceuticals
ACHN
$1.01M 0.26%
+275,000
New +$820K
2018 Q3
0 quarters
INFI
45
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$745K 0.19%
+275,000
New +$569K
2018 Q3
0 quarters
FOMX
46
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$521K 0.13%
91,000
-159,000
-64% -$910K
2015 Q2
13 quarters
BLRX icon
47
BioLineRX
BLRX
$10.2M
$267K 0.07%
417
– –
2013 Q4
19 quarters
GRDX icon
48
GridAI Technologies Corp
GRDX
$31.8M
– –
-1
Closed -$417K –
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return
TFA
Teamwork Financial Advisors San Antonio, Texas $1.1B AUM 39.98% 1-Year Est. Return

Opaleye Management's Q3 2018 Portfolio in Review

As of Q3 2018, Opaleye Management held 48 positions worth $393M, up 1.7% from $386M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management's Q3 2018 filing shows 12 new, 9 increased, 16 reduced and 1 closed positions. Its largest new stake was Xenon Pharmaceuticals: 465,200 shares worth $7.01M. The largest sale was Kyntra Bio, an estimated $9.86M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Opaleye Management's largest Q3 2018 buy was Xenon Pharmaceuticals: 465,200 shares worth $7.01M.
  • Opaleye Management added most to CTI BioPharma Corp. (DE) Common Stock in Q3 2018, an estimated $3.44M increase.
  • Opaleye Management's biggest Q3 2018 reduction was Kyntra Bio, cutting an estimated $9.86M.
  • Opaleye Management fully exited GridAI Technologies Corp in Q3 2018, selling an estimated $417K.
  • Opaleye Management's ten largest holdings make up 57% of its $393M portfolio in Q3 2018.
  • Opaleye Management opened 12 new positions and closed 1 in Q3 2018.
  • Opaleye Management's portfolio value rose 1.7% quarter-over-quarter to $393M.

Based on Opaleye Management's 13F filing for Q3 2018, filed 14 Nov 2018.